Viridian Therapeutics, Inc.\DE (VRDN) Net Equity Issued and Repurchased (2014 - 2025)

Viridian Therapeutics, Inc.\DE's Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at $63.1 million for Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 660.59% year-over-year to $63.1 million in Q4 2025; TTM through Mar 2026 was $72.8 million, a 1485.12% increase from a year earlier, with the FY2025 full-year figure at $63.1 million, up 152.57% from the prior year.
• Net Equity Issued and Repurchased improved to $63.1 million in Q4 2025 per VRDN's latest filing, from $9.8 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $63.1 million in Q4 2025 and bottomed at -$11.3 million in Q4 2024.
• The 5-year median for Net Equity Issued and Repurchased is $19.7 million (2022), against an average of $20.9 million.
• Across the five-year window, Net Equity Issued and Repurchased slumped 173.81% in 2024 and soared 820.19% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $32.4 million in 2021, then declined by 25.31% to $24.2 million in 2022, then sank by 36.94% to $15.3 million in 2023, then sank by 173.81% to -$11.3 million in 2024, then jumped by 660.59% to $63.1 million in 2025.
• Per Business Quant, the three latest VRDN Net Equity Issued and Repurchased figures stand at $63.1 million (Q4 2025), $9.8 million (Q3 2025), and -$143000.0 (Q2 2025).